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and 6 colorectal cancer) over a mean period of 44.3 treatment
days (Range = 14 to 79 days, Median = 44.3 days, SD = 18.9
days). Overall adherence varied from 85.5% to 100% (Mean =
96.7%, Median = 98.9%, SD = 4.3%). The actual vial opening
intervals among the studied patients varied from 1.6 hours to
18.9 hours (Mean = 12.0 h, Median = 12.0 h, SD = 1.7 h, includ-
ing only days with actual twice daily opening). CONCLUSIONS:
Although the results show in general a high degree of overall
adherence and interval regularity, there were several individuals
who exhibited major discrepancies that may potentially endan-
ger therapeutic goals. The adherence data demonstrated here
form the basis for a prospective, open, controlled, two-armed
observational study investigating the impact of pharmaceutical
care as a multidisciplinary patient-oriented service on adherence
and other relevant clinical, subjective and economic outcome
parameters in a larger patient population.
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OBJECTIVES: Chemotherapy induced nausea and vomiting
(CINV) has a negative impact on HRQoL, but little empirical
data showing relation between failure to control CINV and QoL
aspects other than directly related physical symptoms are avail-
able. The aim is to study dimensions of HRQoL more inﬂuenced
by emesis. METHODS: Prospective, multi-center, observational
study on 325 naïve patients recruited at 8 Spanish Oncology Ser-
vices. Consecutive patients undergoing 1st cycle with moderate
to highly emetogenic chemotherapy and scheduled antiemetic
treatment based on granisetron or ondansetron were enrolled.
After chemotherapy (day 0), daily maximum nausea intensity
and number of vomiting episodes were recorded during 5 more
days in a diary card and then FLIE and EORTC QLQ-C30 were
self-administered. Acute CINV was deﬁned as developed in day
0, and delayed CINV as developed or persisting in days 1–5.
Antiemetic “complete” response was deﬁned as: no emesis and
no/mild nausea. RESULTS: Complete response (CI95%) against
acute and delayed CINV were reported by 78.5% (74.0–83.0%)
and 50.0% (44.5–55.0%) of patients. Response rate was not
related to emetogenicity of chemotherapy (p > 0.05). Physical
Functioning, Dyspnoea, Constipation, Diarrhoea and Financial
Diﬁculties from QLQ-C30 were not sensitive to antiemetic
response against CINV (p > 0.05). Reliability of FLIE improved
when the 4-inverted VAS items were discarded, but discrimina-
tion between antiemetic response groups was maintained. Better
response rates were obtained, in the granisetron arm, in the
dimensions Constipation, Nausea and Vomiting of QLQ-C30
and Vomiting scale of FLIE (p < 0.05). A cost minimization
analysis of CINV global antiemetic treatment reﬂects higher
treatment costs rates in the ondansetron arm. CONCLUSIONS:
Complete CINV prevention agrees with literature but evidence
of association between response rate and emotogenicity of
chemotherapy was not found. Both QLQ-C30 and FLIE were
sensitive to type of response showed by the patients. Reliability
of FLIE Spanish version may be improved.
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OBJECTIVES: As an outcome measure for pharmacoeconomic
studies, quality adjusted life year (QALY) is often used. Though
some indirect measurement tool have been proposed, it is not
widely used in clinical trials in Japan. We started QOL data col-
lection along with a clinical trial on breast cancer treatment
(National Surgical Adjuvant Study of Breast Cancer: N-SAS
BC02). The trial has been supported by Comprehensive Support
Project for Oncology Research and Health Outcomes Research.
The aim of this study is to measure QOL of patients receiving
adjuvant chemotherapy after surgery and investigate the validity
of QOL measurement. METHODS: N-SAS BC02 is a random-
ized controlled trial of AC(adriamycin+cyclophosphamide) and
taxanes. Though main outcome measures are disease-free sur-
vival and overall survival, QOL and economic consequences are
secondary concerns. Quality of life was surveyed 6 times during
one year from 300 samples of participants. We adopted EQ-5D
and visual analogue scale (VAS) as utility measurement. We used
Japanese Tariff for calculate utility score from EQ-5D. We also
used Functional Assessment of Cancer Therapy (FACT) for ref-
erence. RESULTS: Average utility score was 0.806 (SD = 0.161)
from EQ-5D. VAS result showed average of 0.744 (SD = 0.189).
Correlation coefﬁcient of EQ-5D and VAS was 0.47. CON-
CLUSIONS: Many participants have problems in dimensions of
Pain/Discomfort and Anxiety/Depression.
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OBJECTIVES: Existing reports of utility values for second-line
advanced non-small cell lung cancer (NSCLC) vary quite widely
and are not optimal for use in health technology assessments
within the UK. The aim of this study was to elicit UK societal-
based utility values for different tumour response statuses and
different grade 3 and 4 toxicities commonly associated with
NSCLC chemotherapy treatments. METHODS: Toxicities con-
sidered were neutropenia, febrile neutropenia, fatigue, diarrhoea,
nausea and vomiting, rash and hair loss. Each health state
described the symptom burden of disease and impact on differ-
ent levels of functioning (physical, emotional, sexual, and social).
The disutility related to each response status and toxicity was
estimated and combined to give health state values. Existing
health state descriptions of metastatic breast cancer were revised
to make them suitable as descriptions of NSCLC patients receiv-
ing second-line chemotherapy. The existing health states were
used in cognitive debrief interviews with oncologists (n = 5) and
oncology specialist nurses (n = 5). Changes were made as sug-
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gested by these clinical experts. The resulting health states (n =
17) were piloted and used in a societal-based valuation study 
(n = 100). Participants rated half of the total health states in a
standard gamble interview to derive health state utility scores.
Data were analysed using a mixed model analysis. This study
was conducted in line with standard NICE appraisal methodol-
ogy. RESULTS: All tumour response statuses and toxicities were
independent signiﬁcant predictors of utility (p < 0.001). Stable
disease with no toxicity (our base state) had a utility value of
0.65. Utility scores ranged from 0.67 (responding disease with
no toxicity) to 0.47 for progressive disease. CONCLUSION:
This study reﬂects the value that society places on the avoidance
of disease progression and severe toxicities associated with the
treatment of second-line advanced NSCLC.
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OBJECTIVES: Assess inter-rater agreement (patient and parent)
of HUI utility scores for survivors of brain tumors in childhood.
METHODS: Patients and their parents were interviewed twice
using an interviewer-administered HUI questionnaire. Agree-
ment was assessed using intra-class correlation coefﬁcients
(ICC). T-tests assessed the statistical signiﬁcance of differences in
mean overall and pain utility scores between patients reporting
no pain and those reporting pain. RESULTS: HUI data for 40
brain tumor survivors (57.5% female) were collected during late
2000 and early 2001 (interview 1). To date, 26 re-assessment
interviews have been completed during 2005–2006 (interview 2).
One patient has died. Patient mean age was 6.8 years at diag-
nosis and 16.2 years at the ﬁrst survey. For overall health-related
quality of life scores (HRQL), there was substantial inter-rater
agreement (HUI3 ICC = 0.723, p < 0.001) at interview 1 and
moderate agreement (HUI3 ICC = 0.561, p = 0.03) at interview
2. There was substantial to almost perfect agreement at both
interviews for attributes considered readily observable (vision,
speech, ambulation and dexterity) (ICC 0.783 to 0.988, p <
0.001). For less observable attributes (emotion, cognition, pain),
agreement was moderate or less (ICC from 0.101 to 0.611, p =
0.372 to 0.002). Statistically signiﬁcant differences were detected
for both mean HRQL (difference = 0.36, p = 0.003) and pain
(difference = 0.24, p = 0.003) scores between patients reporting
pain (n = 14) and those pain free at interview 1. At interview 2,
the mean scores were not statistically signiﬁcantly different
between patients reporting pain (n = 7) and those with no pain
(n = 19, HRQL p = 0.317; pain attribute p = 0.067). CON-
CLUSIONS: There was moderate or better inter-rater agreement
for HRQL and all readily observable single-attribute HUI3
scores both at interview 1 and interview 2. Levels of ICC are
consistent with previous studies of childhood cancer survivors in
Brazil and Uruguay. Differences in mean HRQL and pain scores
between patients with and without pain is evidence of discrimi-
native validity.
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OBJECTIVES: Assess the reliability and validity of a newly
developed patient-reported outcome (PRO) questionnaire for
metastatic colorectal cancer (mCRC) patients. METHODS: The
questionnaire, which includes ﬁve scales [NCCN/FACT Col-
orectal Cancer Scale (CS), De Novo Bother Life Quality Index
(DNB), EORTC QLQ-C30 Global Quality of Life Subscale
(EORTC), EQ-5D Index Scale (EQ-5D) and the EQ-5D visual
analog scale (VAS)], was administered every four weeks to
mCRC patients in a Phase III clinical trial. Its psychometric prop-
erties were evaluated, including internal consistency reliability,
test-retest reliability, construct validity, known groups validity,
and responsiveness. RESULTS: A total of 391 mCRC patients
completed the questionnaire at baseline and at least one follow-
up assessment. Internal consistency was demonstrated with
Cronbach’s alphas for all scales >0.70 (range: 0.81–0.92). The
4-week test-retest reliability, as measured by the intra-class 
correlation, among patients who had stable EQ-5D scores and
also among patients whose ECOG performance status was
unchanged, ranged from 0.58–0.76 and 0.61–0.76, respectively.
Construct validity was demonstrated based on proposed inter-
scale correlations being borne out [e.g., CS was highly correlated
with EORTC (0.72)]. Known groups validity was evaluated by
examining the scale scores of patients categorized by their ECOG
performance status. Other than DNB, patients with better per-
formance status reported better scores than those with a lower
performance status (ECOG = 0 or 1 vs. 2). Signiﬁcant differences
were reported on all scales (p < 0.001) at baseline and week 8
with the exception of DNB. Responsiveness, as measured by
Guyatt’s statistic, was >0.20 for all scales from baseline to week
8 (range 0.56–1.13) and from weeks 4 to 12 (range 0.29–1.11).
EORTC and EQ-5D Index scales were the most responsive.
CONCLUSIONS: Results provide preliminary evidence of the
reliability, validity, and responsiveness of the questionnaire.
Additional work is needed to estimate the minimal clinical
important difference and more fully investigate test-retest 
reliability.
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OBJECTIVE: We examined demographics, clinical characteris-
tics, Health Related Quality of Life (HRQoL) and satisfaction
with care across two treatments (radical prostatectomy or RP
and external beam radiation or EBRT) for older prostate cancer
(PCa) patients. METHODS: In this prospective cohort study we
recruited 215 newly diagnosed PCa patients, 65 years or older,
from the urology clinics of an urban academic hospital and a VA
hospital. Patients completed generic (SF-36), prostate speciﬁc
(UCLA-PCI) HRQoL, and satisfaction with care (CSQ-8)
surveys prior to treatment and at 3, 6, and 12 months post-
treatment. Clinical and demographic data were obtained using
hospital based databases. Repeated measures ANOVA was used
to examine changes in generic and PCa speciﬁc HRQoL across
treatments. Log-linear regression was used to determine factors
associated with 12 month HRQoL. Survival curves were used to
